Simulations Plus (NASDAQ:SLP) Director Walter Woltosz Sells 4,177 Shares

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter Woltosz sold 4,177 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $18.44, for a total value of $77,023.88. Following the completion of the transaction, the director owned 3,202,131 shares of the company’s stock, valued at $59,047,295.64. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Simulations Plus Trading Up 0.0%

SLP stock opened at $18.36 on Tuesday. The firm has a 50-day moving average of $16.25 and a two-hundred day moving average of $15.48. The firm has a market capitalization of $370.97 million, a PE ratio of -5.87 and a beta of 1.30. Simulations Plus, Inc. has a one year low of $11.09 and a one year high of $21.01.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Thursday, April 9th. The technology company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.27 by $0.08. Simulations Plus had a negative net margin of 77.96% and a positive return on equity of 16.21%. The business had revenue of $24.29 million during the quarter, compared to the consensus estimate of $21.66 million. On average, equities research analysts anticipate that Simulations Plus, Inc. will post 0.8 earnings per share for the current year.

Analyst Ratings Changes

SLP has been the topic of several recent analyst reports. Wall Street Zen lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. William Blair cut Simulations Plus from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 17th. TD Cowen dropped their target price on Simulations Plus from $19.00 to $16.00 and set a “hold” rating on the stock in a report on Friday, April 10th. Weiss Ratings raised shares of Simulations Plus from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Finally, Craig Hallum cut shares of Simulations Plus from a “buy” rating to a “hold” rating and set a $18.50 price target for the company. in a report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $19.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in shares of Simulations Plus during the 2nd quarter worth about $25,000. Quarry LP bought a new stake in shares of Simulations Plus in the 3rd quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its holdings in Simulations Plus by 343.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,983 shares of the technology company’s stock worth $73,000 after buying an additional 3,084 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Simulations Plus by 59.3% during the first quarter. PNC Financial Services Group Inc. now owns 4,485 shares of the technology company’s stock valued at $53,000 after acquiring an additional 1,669 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in Simulations Plus during the first quarter valued at approximately $54,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.